Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

ENTRY-DM Interdisciplinary doctoral training on oligonucleotide-based therapies for myotonic dystrophy

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 March 2025 to 28 February 2029
Status
Running
EU funding
€3.7m
Total cost
—
Partners
31 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101169266

What the project is doing

In the project's own words, from its summary on CORDIS.

Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of diagnostics, healthcare and treatment. Myotonic Dystrophy (DM), the most predominant inherited muscular dystrophy in adults, impacts 60,000-70,000 individuals in Europe. Its complex genetic and clinical variability result in a lack of robust genotype-phenotype correlations, which complicates the understanding of tissue-specific disease mechanisms, the development of effective therapies and the stratification of patients into well-defined clinical groups for clinical trial purposes.

In recent years, Antisense Oligonucleotides (ASO) have emerged as promising therapeutics, notably in neuromuscular disorders. However, previous clinical trials in DM have failed due the reduced efficacy and bioavailability of the ASO tested. ENTRY-DM aims to train 14 DCs in translational research, through the combination of basic and clinical competencies across multiple disciplines, as well as strong soft and transferable skills.

Our interdisciplinary network seeks to enhance scientific and technological knowledge, spanning from disease mechanisms, ASO design and delivery strategies, to clinical trial preparedness, using innovative multidisciplinary approaches and best practices. The consortium includes experts in DM research, bioengineering of model systems for preclinical drug screening, ASO chemistry, as well as clinical and neuropsychological assessment.

Close collaborations with multi-sectoral partners will address the challenges in technology transfer, providing high-quality bench-to-bedside training to the next generation of researchers. Through these efforts, ENTRY-DM will catalyze ASO therapeutic development towards upcoming impeding clinical trials, establishing solid foundations for future clinical applications, increased investment and entrepreneurship ventures in the field of DM and other related diseases.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
Sib Swiss Institute of BioinformaticsGenfSwitzerlandAssociatedpartner
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Arthex Biotech SLValenciaSpainAssociatedpartner
Biobam Bioinformatics SLValenciaSpainAssociatedpartner
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainParticipant
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Universitat De ValenciaValenciaSpainParticipant
Association Institut De MyologieParisFranceAssociatedpartner
Centre D'etude Des Cellules SouchesCorbeil-EssonnesFranceParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceAssociatedpartner
Euro-DymaParisFranceAssociatedpartner
Sorbonne UniversiteParisFranceAssociatedpartner
Universite D'evry-Val D'essoneEvryFranceAssociatedpartner
Universite Paris CiteParisFranceParticipant
Genartis SRLVeronaItalyParticipant
Universita Degli Studi Di Roma La SapienzaRomaItalyAssociatedpartner
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Universita Degli Studi Di VeronaVeronaItalyAssociatedpartner
Eatris EricAmsterdamNetherlandsAssociatedpartner
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Stichting Radboud UniversiteitNijmegenNetherlandsAssociatedpartner
Uniwersytet Im. Adama Mickiewicza WpoznaniuPoznanPolandParticipant
Goeteborgs UniversitetGoeteborgSwedenAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
Myotonic Dystrophy FoundationOaklandUnited StatesAssociatedpartner
Sanofi GenzymeCambridgeUnited StatesAssociatedpartner
The Regents of the University of CaliforniaOaklandUnited StatesAssociatedpartner
University of FloridaGainesvilleUnited StatesAssociatedpartner
Virginia Commonwealth UniversityRichmond, VAUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI